Pharmaxis Ltd (AU:SNT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Syntara Limited, formerly known as Pharmaxis, has undergone a significant transformation to focus on innovative healthcare solutions, reducing their team and expenses to concentrate on promising drug candidates like SNT-5505. The company achieved full recruitment for its phase 2 trial in myelofibrosis and secured non-dilutive funding for myelodysplastic syndrome studies, reinforcing the value of its lead asset. With upcoming data presentations and FDA engagements, Syntara is poised for further advancements in its hematology program.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
